Science 37 Holdings Zukünftiges Wachstum

Future Kriterienprüfungen 1/6

Science 37 Holdings wird ein Gewinn- und Umsatzwachstum von 66.7% bzw. 17.5% pro Jahr prognostiziert, während der Gewinn pro Aktie um 67.9% pro Jahr wachsen soll.

Wichtige Informationen

66.7%

Wachstumsrate der Gewinne

67.9%

EPS-Wachstumsrate

Life Sciences Gewinnwachstum	16.2%
Wachstumsrate der Einnahmen	17.5%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	30 Jan 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Science 37 Holdings, Inc. (NASDAQ:SNCE) Might Not Be As Mispriced As It Looks

Dec 18

Investors Continue Waiting On Sidelines For Science 37 Holdings, Inc. (NASDAQ:SNCE)

Apr 17

Science 37, Syapse team for faster patient enrollment in cancer trials

Aug 18

Science 37 reports Q2 mixed earnings; narrows FY22 guidance

Aug 11

Results: Science 37 Holdings, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates

May 13

Science 37 Holdings (NASDAQ:SNCE) Is In A Good Position To Deliver On Growth Plans

Apr 11

Science 37: Pioneering Decentralized Clinical Trials

Jan 02

We Think Science 37 Holdings (NASDAQ:SNCE) Can Afford To Drive Business Growth

Nov 04

Gewinn- und Umsatzwachstumsprognosen

NasdaqCM:SNCE - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	95	3	-18	30	3
12/31/2025	75	-25	-28	3	3
12/31/2024	63	-38	-44	-9	4
12/31/2023	58	-73	-81	-46	4
9/30/2023	60	-125	-74	-48	N/A
6/30/2023	62	-134	-84	-58	N/A
3/31/2023	66	-121	-98	-67	N/A
12/31/2022	70	-51	-107	-75	N/A
9/30/2022	75	-50	-115	-82	N/A
6/30/2022	73	-41	-108	-78	N/A
3/31/2022	66	-43	-83	-57	N/A
12/31/2021	60	-94	-57	-36	N/A
9/30/2021	50	-42	-37	-23	N/A
6/30/2021	43	-35	-33	-23	N/A
3/31/2021	33	-33	-33	-26	N/A
12/31/2020	24	-32	-32	-25	N/A
12/31/2019	14	-18	-20	-16	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: SNCE wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: SNCE wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: SNCE wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: SNCEDie Einnahmen des Unternehmens (17.5% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.4% pro Jahr).

Hohe Wachstumseinnahmen: SNCEDie Einnahmen des Unternehmens (17.5% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von SNCE in 3 Jahren voraussichtlich hoch sein wird

Science 37 Holdings Zukünftiges Wachstum

Future Kriterienprüfungen 1/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Price target decreased by 51% to US$13.83

Forecast to breakeven in 2026

Science 37 Holdings, Inc. Provides Earnings Guidance for the Fiscal Year Ending December 31, 2023

Price target decreased by 20% to US$1.50

Consensus estimates of losses per share improve by 11%

Price target decreased by 9.4% to US$1.81

Recent updates

Science 37 Holdings, Inc. Surpasses Enrollment Goals, Accelerates Phase 2 Rare Disease Clinical Trial

Science 37 Holdings, Inc. Metasite Undergoes Successful FDA Inspection, Marking Major Milestone in Virtual Site Quality Assurance and Compliance

Science 37 Holdings, Inc. Delivers 22x Faster Enrollment Than Traditional Methods in Phase 3 Asthma Clinical Trial

Science 37 Holdings Files Form 15

Science 37 Holdings, Inc.(NasdaqCM:SNCE) dropped from NASDAQ Composite Index

eMed, LLC completed the acquisition of Science 37 Holdings, Inc. (NasdaqCM:SNCE).

eMed, LLC entered into a definitive merger agreement to acquire Science 37 Holdings, Inc. (NasdaqCM:SNCE) $37.8 million.

Price target decreased by 51% to US$13.83

eMed, LLC entered into a definitive merger agreement to acquire Science 37 Holdings, Inc. (NasdaqCM:SNCE) $37.8 million.

New major risk - Share price stability

Forecast to breakeven in 2026

Science 37 Holdings Regains Compliance with Minimum Closing Bid Price Requirement for Continued Listing on NASDAQ Capital Market

Science 37 Holdings, Inc. (NASDAQ:SNCE) Might Not Be As Mispriced As It Looks

Science 37 Holdings, Inc. Provides Earnings Guidance for the Fiscal Year Ending December 31, 2023

Price target decreased by 20% to US$1.50

New major risk - Revenue and earnings growth

New minor risk - Shareholder dilution

Science 37 Holdings, Inc. to Report Q3, 2023 Results on Nov 07, 2023

CEO & Director exercised options and sold US$64k worth of stock

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Science 37 Holdings, Inc. to Report Q2, 2023 Results on Aug 08, 2023

Science 37 Holdings Announces Nasdaq Approves an Additional 180 Calendar Day Compliance Period to Regain Compliance with the Minimum Bid Requirement

Consensus estimates of losses per share improve by 11%

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Investors Continue Waiting On Sidelines For Science 37 Holdings, Inc. (NASDAQ:SNCE)

Price target decreased by 9.4% to US$1.81

High number of new and inexperienced directors

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Science 37 Holdings, Inc. (NasdaqGM:SNCE) acquired Life Sciences Platform of Vault Health.

Science 37 Holdings Receives A Deficiency Notification Letter from Nasdaq Regarding Minimum Bid Price

Consensus revenue estimates fall by 15%

Price target decreased to US$3.00

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Forecast to breakeven in 2022

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Science 37 Holdings, Inc. Revises Earnings Guidance for the Full Year 2022

Science 37 Holdings, Inc. to Report Q3, 2022 Results on Nov 10, 2022

Science 37 Holdings, Inc. Announces Board Changes

Science 37®Holdings, Inc. Announces Changes to its Board

Science 37 Holdings, Inc. Appoints Michael Shipton as Chief Commercial Officer

Science 37 Holdings, Inc. and Syapse Partner to Enable Faster Patient Enrollment in Oncology Clinical Trials

Consensus forecasts updated

Science 37, Syapse team for faster patient enrollment in cancer trials

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Science 37 Holdings, Inc. Provides Revenue Guidance for Year Ending December 31, 2022

Science 37 reports Q2 mixed earnings; narrows FY22 guidance

Science 37 Holdings, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Oncology Clinical Trial Execs to Increase Decentralization, Science 37 Survey Indicates

Consensus estimates of losses per share improve by 72%

Results: Science 37 Holdings, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates

Science 37 Introduces Virtual Site Model to Rescue Slow Enrolling Clinical Trials

Science 37® Announces NextGen SaaS Release to Fully Orchestrate Decentralized Study Conduct

First quarter 2022 earnings: Revenues exceed analyst expectations

Science 37 Holdings, Inc. Provides Revenue Guidance for the Fiscal Year Ending December 31, 2022

Price target decreased to US$11.33

Science 37 Holdings, Inc. to Report Q1, 2022 Results on May 09, 2022

Science 37 Holdings (NASDAQ:SNCE) Is In A Good Position To Deliver On Growth Plans

Science 37 Holdings, Inc. Adds Shaalan Beg to Its Global Management Team

Consensus revenue estimates fall by 12%

Science 37: Pioneering Decentralized Clinical Trials

Third quarter 2021 earnings: EPS and revenues exceed analyst expectations

Third quarter 2021 earnings released: US$3.23 loss per share

We Think Science 37 Holdings (NASDAQ:SNCE) Can Afford To Drive Business Growth

No independent directors

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken